Pharma: Clinic Roundup
Tuesday, August 6, 2013
Sanofi Pasteur Ltd., the vaccines division of Sanofi SA, of Paris, initiated a Phase III program called Cdiffense to evaluate the safety, immunogenicity and efficacy of its investigational vaccine to prevent primary symptomatic Clostridium difficile infection (CDI) in at-risk individuals.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.